---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-090181"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-08-14T20:35:17+00:00"
generated_at: "2026-08-14T20:44:47.678771+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma Q3 FY26: LYMPHIR revenue $1.5M, net loss $8.9M, cash $17M

## Summary
- Q3 FY26 revenue $1.5M from LYMPHIR (vs $0 prior year); nine-month revenue $7.1M.
- Net loss $8.9M ($0.34/share) for Q3; $38.3M ($1.64/share) for nine months.
- Cash and equivalents $17.0M at June 30, 2026; raised $4.5M offering, $9.7M warrants, $10M loan.
- LYMPHIR now at 44 institutions; institutional vial orders up 31%, new institutions up 80%; July orders 383 vials.
- G&A includes $19.7M non-recurring contract cancellation charge in March 2026; commercial team expanded to 29.

## SEC filing metadata
- accession: 0001213900-26-090181
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-08-14T20:35:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/0001213900-26-090181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/ea0302227-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-090181
- JSON: https://secwatch.observer/filing/0001213900-26-090181.json
- Plain text: https://secwatch.observer/filing/0001213900-26-090181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.